JP Morgan Chase’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-60,453
| Closed | -$951K | – | 7841 |
|
|
2024
Q1 | $951K | Sell |
60,453
-26,695
| -31% | -$411K | ﹤0.01% | 4385 |
|
|
2023
Q4 | $1.41M | Buy |
87,148
+4,447
| +5% | +$56.7K | ﹤0.01% | 4100 |
|
|
2023
Q3 | $1.05M | Buy |
82,701
+2,347
| +3% | +$32.4K | ﹤0.01% | 4032 |
|
|
2023
Q2 | $1.13M | Buy |
80,354
+11,909
| +17% | +$170K | ﹤0.01% | 3966 |
|
|
2023
Q1 | $1.06M | Sell |
68,445
-5,567
| -8% | -$92.9K | ﹤0.01% | 3992 |
|
|
2022
Q4 | $1.21M | Sell |
74,012
-5,357
| -7% | -$87.1K | ﹤0.01% | 3918 |
|
|
2022
Q3 | $1.47M | Buy |
79,369
+37,122
| +88% | +$583K | ﹤0.01% | 3725 |
|
|
2022
Q2 | $556K | Sell |
42,247
-321,234
| -88% | -$3.55M | ﹤0.01% | 4484 |
|
|
2022
Q1 | $3.37M | Buy |
363,481
+239,535
| +193% | +$2.04M | ﹤0.01% | 3332 |
|
|
2021
Q4 | $1.21M | Buy |
123,946
+97,250
| +364% | +$1.83M | ﹤0.01% | 4244 |
|
|
2021
Q3 | $907K | Sell |
26,696
-571
| -2% | -$18.2K | ﹤0.01% | 4387 |
|
|
2021
Q2 | $998K | Buy |
27,267
+3,732
| +16% | +$144K | ﹤0.01% | 4295 |
|
|
2021
Q1 | $1.05M | Buy |
23,535
+6,318
| +37% | +$294K | ﹤0.01% | 4185 |
|
|
2020
Q4 | $983K | Buy |
17,217
+3,270
| +23% | +$194K | ﹤0.01% | 3980 |
|
|
2020
Q3 | $691K | Buy |
13,947
+1,317
| +10% | +$64.5K | ﹤0.01% | 3840 |
|
|
2020
Q2 | $754K | Buy |
12,630
+5,841
| +86% | +$312K | ﹤0.01% | 3665 |
|
|
2020
Q1 | $279K | Sell |
6,789
-80,401
| -92% | -$4.46M | ﹤0.01% | 4128 |
|
|
2019
Q4 | $5.43M | Buy |
87,190
+80,974
| +1,303% | +$3.85M | ﹤0.01% | 2607 |
|
|
2019
Q3 | $211K | Buy |
6,216
+2,159
| +53% | +$63.9K | ﹤0.01% | 4610 |
|
|
2019
Q2 | $95K | Buy |
4,057
+1,913
| +89% | +$44.8K | ﹤0.01% | 4956 |
|
|
2019
Q1 | $50K | Sell |
2,144
-102
| -5% | -$2.67K | ﹤0.01% | 5137 |
|
|
2018
Q4 | $47K | Sell |
2,246
-615
| -21% | -$15.1K | ﹤0.01% | 5107 |
|
|
2018
Q3 | $111K | Sell |
2,861
-188,323
| -99% | -$6.96M | ﹤0.01% | 4911 |
|
|
2018
Q2 | $7.52M | Sell |
191,184
-96,578
| -34% | -$2.84M | ﹤0.01% | 2366 |
|
|
2018
Q1 | $5.77M | Buy |
287,762
+112,581
| +64% | +$2.85M | ﹤0.01% | 2460 |
|
|
2017
Q4 | $3.97M | Buy |
+175,181
| New | +$3.43M | ﹤0.01% | 2864 |
|
Other funds holding DCPH
JP Morgan Chase's DCPH Position: Q2 2024 in Review
JP Morgan Chase sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 60,453 shares — an estimated $951K sold.
JP Morgan Chase first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $7.52M in Q2 2018. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- JP Morgan Chase reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- JP Morgan Chase sold 60,453 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $951K.
- JP Morgan Chase first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- JP Morgan Chase's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $7.52M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.